Profile data is unavailable for this security.
About the company
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
- Revenue in USD (TTM)563.95m
- Net income in USD-479.45m
- Incorporated2011
- Employees1.78k
- LocationGuardant Health Inc3100 Hanover StreetPALO ALTO 94304United StatesUSA
- Phone+1 (650) 290-7575
- Fax+1 (302) 531-3150
- Websitehttps://guardanthealth.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rocket Pharmaceuticals Inc | 0.00 | -245.60m | 2.12bn | 268.00 | -- | 4.30 | -- | -- | -2.94 | -2.94 | 0.00 | 5.46 | 0.00 | -- | -- | 0.00 | -43.93 | -35.26 | -47.67 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0412 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
| Keros Therapeutics Inc | 151.00k | -152.99m | 2.18bn | 136.00 | -- | 5.81 | -- | 14,467.72 | -5.19 | -5.19 | 0.0051 | 10.43 | 0.0005 | -- | 2.11 | 1,110.29 | -45.21 | -35.95 | -48.12 | -38.07 | -- | -- | -101,319.20 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
| Arvinas Inc | 78.50m | -367.30m | 2.24bn | 445.00 | -- | 3.38 | -- | 28.56 | -6.62 | -6.62 | 1.45 | 9.71 | 0.061 | -- | 157.00 | 176,404.50 | -28.35 | -22.01 | -36.10 | -26.47 | -- | -- | -464.71 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Maravai Lifesciences Holdings Inc | 288.95m | -119.03m | 2.26bn | 650.00 | -- | 5.41 | -- | 7.82 | -0.901 | -0.901 | 2.19 | 1.66 | 0.1533 | 3.15 | 2.99 | 444,530.80 | -7.34 | 12.67 | -9.75 | 15.46 | 48.52 | 74.79 | -47.89 | 37.32 | 7.41 | -0.3566 | 0.4134 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
| Intellia Therapeutics Inc | 36.28m | -481.19m | 2.27bn | 526.00 | -- | 2.09 | -- | 62.53 | -5.42 | -5.42 | 0.4106 | 11.29 | 0.0257 | -- | 1.80 | 68,963.88 | -34.11 | -31.34 | -37.31 | -34.53 | -- | -- | -1,326.51 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
| Dyne Therapeutics Inc | 0.00 | -257.40m | 2.28bn | 143.00 | -- | 4.75 | -- | -- | -3.97 | -3.97 | 0.00 | 5.49 | 0.00 | -- | -- | 0.00 | -63.48 | -52.81 | -67.12 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
| Kymera Therapeutics Inc | 79.41m | -154.59m | 2.29bn | 186.00 | -- | 3.23 | -- | 28.90 | -2.50 | -2.50 | 1.29 | 11.59 | 0.1072 | -- | 29.69 | 424,668.40 | -20.86 | -23.03 | -22.67 | -27.64 | -- | -- | -194.67 | -207.82 | -- | -- | 0.0032 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| Guardant Health Inc | 563.95m | -479.45m | 2.30bn | 1.78k | -- | 14.47 | -- | 4.08 | -4.28 | -4.28 | 5.04 | 1.30 | 0.3321 | 4.00 | 6.06 | 317,002.80 | -28.23 | -22.26 | -31.99 | -24.59 | 59.74 | 64.62 | -85.02 | -97.07 | 6.24 | -12.04 | 0.8778 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
| Geron Corp | 237.00k | -184.13m | 2.31bn | 141.00 | -- | 8.64 | -- | 9,732.34 | -0.3246 | -0.3246 | 0.0004 | 0.455 | 0.0008 | -- | 0.0988 | 1,680.85 | -62.99 | -51.32 | -92.09 | -64.90 | -- | -- | -77,690.72 | -19,949.13 | -- | -- | 0.2484 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| Sana Biotechnology Inc | 0.00 | -283.26m | 2.31bn | 328.00 | -- | 7.18 | -- | -- | -1.46 | -1.46 | 0.00 | 1.45 | 0.00 | -- | -- | 0.00 | -40.81 | -38.99 | -46.74 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
| Vericel Corp | 197.52m | -3.18m | 2.31bn | 314.00 | -- | 10.12 | 1,476.73 | 11.72 | -0.0684 | -0.0684 | 4.15 | 4.72 | 0.6304 | 4.26 | 3.77 | 629,031.90 | -1.02 | -3.07 | -1.17 | -3.50 | 68.64 | 67.87 | -1.61 | -4.49 | 4.21 | -- | 0.0004 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Vera Therapeutics Inc | 0.00 | -95.99m | 2.37bn | 51.00 | -- | 18.99 | -- | -- | -2.28 | -2.28 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.54 | -- | -74.10 | -- | -- | -- | -- | -- | -- | -- | 0.3291 | -- | -- | -- | -7.79 | -- | -- | -- |
| Twist Bioscience Corp | 277.49m | -192.14m | 2.38bn | 919.00 | -- | 4.28 | -- | 8.59 | -3.35 | -3.35 | 4.83 | 9.63 | 0.3565 | 4.87 | 7.04 | 301,943.40 | -24.68 | -30.50 | -27.12 | -33.84 | 38.29 | 36.02 | -69.24 | -113.33 | 5.06 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
| CG Oncology Inc | 204.00k | -67.80m | 2.42bn | 61.00 | -- | -- | -- | 11,847.53 | -1.07 | -1.07 | 0.0032 | 2.91 | -- | -- | -- | 3,344.26 | -- | -- | -- | -- | -- | -- | -23,826.96 | -- | -- | -- | 0.002 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Hims & Hers Health Inc | 872.00m | -23.55m | 2.42bn | 1.05k | -- | 6.99 | -- | 2.77 | -0.1131 | -0.1131 | 4.17 | 1.61 | 2.16 | 7.13 | 195.17 | 833,652.00 | -5.83 | -- | -7.02 | -- | 81.99 | -- | -2.70 | -- | 2.74 | -- | 0.00 | -- | 65.49 | -- | 64.15 | -- | -- | -- |
| Denali Therapeutics Inc | 330.53m | -145.22m | 2.44bn | 445.00 | -- | 2.30 | -- | 7.39 | -1.09 | -1.09 | 2.39 | 7.45 | 0.2529 | -- | -- | 742,766.30 | -11.11 | -14.98 | -13.37 | -17.71 | -- | -- | -43.94 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
Data as of May 03 2024. Currency figures normalised to Guardant Health Inc's reporting currency: US Dollar USD
45.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 10.80m | 8.88% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 8.74m | 7.18% |
| Deep Track Capital LPas of 02 Apr 2024 | 7.00m | 5.75% |
| Baillie Gifford & Co.as of 31 Mar 2024 | 6.23m | 5.12% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 4.74m | 3.89% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2023 | 4.00m | 3.29% |
| Eventide Asset Management LLCas of 31 Dec 2023 | 3.89m | 3.20% |
| AllianceBernstein LPas of 31 Dec 2023 | 3.71m | 3.05% |
| Temasek Holdings Pte Ltd. (Investment Management)as of 31 Dec 2023 | 3.67m | 3.02% |
| Parkwood LLCas of 31 Dec 2023 | 2.80m | 2.30% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
